Ionis Pharmaceuticals

Ionis Pharmaceuticals (IONS) is the lead sponsor of 20 active clinical trials listed on ClinicalTrials.gov^[4], including 11 Phase 3^[1], 4 Phase 2^[2], 5 Phase 1^[3].

Trial NCT05071300^[5] evaluates Eplontersen in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy with a target enrollment of 151 participants. Trial NCT06914609^[6] evaluates ION582 in Angelman Syndrome with a target enrollment of 158 participants. Trial NCT05130450^[7] evaluates Olezarsen in Familial Chylomicronemia Syndrome with a target enrollment of 60 participants.

IONS has 4 Form 4 insider filings recorded at the SEC in the past 30 days^[8].